Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2008 2
2009 1
2010 2
2011 3
2012 4
2013 3
2014 7
2015 11
2016 16
2017 9
2018 13
2019 14
2020 15
2021 23
Text availability
Article attribute
Article type
Publication date

Search Results

115 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean manuel rodriguez (462 results)?
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. Among authors: rodrigues m. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Pujade-Lauraine E, et al. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Lancet Oncol. 2017. PMID: 28754483 Free article. Clinical Trial.
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E. Friedlander M, et al. Among authors: rodrigues m. Lancet Oncol. 2018 Aug;19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7. Epub 2018 Jul 17. Lancet Oncol. 2018. PMID: 30026002 Free PMC article. Clinical Trial.
[2019 international oncology news: A compendium].
Magné N, Sabatier R, Wislez M, André T, Rodrigues M, Hervé L, Thiery-Vuillemin A, Penel N, Bouleuc C, Bay JO. Magné N, et al. Among authors: rodrigues m. Bull Cancer. 2020 Feb;107(2):148-156. doi: 10.1016/j.bulcan.2020.01.010. Epub 2020 Feb 10. Bull Cancer. 2020. PMID: 32057466 Review. French.
[KRASG12C mutation is not undruggable anymore].
Rodrigues M. Rodrigues M. Bull Cancer. 2020 Feb;107(2):145. doi: 10.1016/j.bulcan.2019.11.008. Epub 2020 Jan 16. Bull Cancer. 2020. PMID: 31955868 French. No abstract available.
[What should we remember from 2020?].
Bay JO, Andre T, Bouleuc C, Gandemer V, Magne N, Orbach D, Pellier I, Penel N, Rodrigues M, Thariat J, Thiery-Villemin A, Wisley M, L'Allemain G, Robert J; Comité de rédaction du Bulletin du cancer. Bay JO, et al. Among authors: rodrigues m. Bull Cancer. 2021 Jan;108(1):55-66. doi: 10.1016/j.bulcan.2020.12.002. Epub 2021 Jan 6. Bull Cancer. 2021. PMID: 33419531 Review. French.
[Editorial of the French Society of Cancer].
Rodrigues M; et l'ensemble des membres du Bureau de la Société Française du Cancer. Rodrigues M, et al. Bull Cancer. 2019 Jan;106(1):4. doi: 10.1016/j.bulcan.2019.01.003. Bull Cancer. 2019. PMID: 30709566 French. No abstract available.
115 results